New combo therapy targets Hard-to-Treat bile duct cancer
NCT ID NCT04781192
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether combining two drugs—regorafenib (a targeted therapy) and durvalumab (an immunotherapy)—can help people with advanced biliary tract cancer that has stopped responding to chemotherapy. About 40 participants will receive both drugs to see if the combination is safe and can slow cancer growth. The goal is to find a new treatment option for this difficult-to-treat cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- regorafenib and durvalumab
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced biliary tract cancer who have run out of standard chemotherapy options.
- What could go wrong
- This is an early-phase trial with only 40 participants, so results may not apply to everyone. The drug combination may cause significant side effects and may not improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The University of Kansas Medical Center
Westwood, Kansas, 66205, United States
-
The University of Kansas Medical Center
North Kansas City, Missouri, 64116, United States
-
University of Kansas Cancer Center - Lee's Summit
Lee's Summit, Missouri, 64064, United States
-
University of Kansas Cancer Center - North
Kansas City, Missouri, 64154, United States
-
University of Kansas Cancer Center - Overland Park
Overland Park, Kansas, 66210, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can sound waves supercharge immunotherapy against bile duct cancer?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- Can a pill target Hard-to-Treat bile duct cancers? a new drug puts FGFR2 mutations to the test
- Can matching drugs to tumor genes beat biliary cancer?
- Can freezing tumors boost immunotherapy in hard-to-treat bile duct cancers?
- Can a targeted antibody boost chemotherapy for a rare bile duct cancer?